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MinireviewVariation on an Src-like Theme
Src, the activation loop is stabilized in its active confor-Stephen C. Harrison*
mation by phosphorylation of one or more residuesDepartments of Biological Chemistry and Molecular
within it.Pharmacology and of Pediatrics
Kinases like Src and Abl have an elaborate built-inHarvard Medical School
regulatory apparatus, made primarily from structural el-Children’s Hospital
ements outside the kinase domain. In Src and its rela-Howard Hughes Medical Institute
tives, the control machinery has three critical compo-Boston, Massachusetts 02115
nents, which I will call the “switch,” the “clamp,” and
the “latch.” The switch is the kinase-domain activation
loop and the coupling of its conformational state to aThe modularity of protein architecture and the diver-
transition between active and inactive conformations ofsity of protein domains hint at a vast combinatorial
the whole domain (including a shift in the C-helix). Therichness. But evolution appears to have been relatively
clamp is an assembly of the SH2 and SH3 domains (theconservative about selecting new combinations. When
“regulatory apparatus”) on the back side of the kinase.a particular grouping of domains within a polypeptide
The SH2 domain abuts the large lobe; the SH3 domain,chain can perform a concerted function, that combina-
the small lobe. The linker connecting SH2 and kinase istion tends to reappear in multiple genomic contexts. In
an adaptor element that runs through the ligand bindingother words, once a molecular solution to a functional
groove of the SH3 domain and interfaces it to the kinase.problem has emerged, it is reused rather than rein-
In Src-family kinases, the latch is a short, tyrosine-con-vented.
taining, C-terminal tail. When the tyrosine is phosphory-
lated, it binds the SH2 domain and fastens the clampConsider the set of three domains found in Src family
in place. In physico-chemical terms, it stabilizes thekinases—the Src-homology 3 or “SH3,” the Src-homol-
assembled state of the regulatory apparatus (Xu et al.,ogy 2 or “SH2,” and the protein tyrosine kinase or “PTK”
1999).domains, respectively (Figure 1). Each domain can carry
Alignment of sequences with those of Src-familyout its specific recognition or enzymatic function inde-
members has left little doubt that Abl and Arg—andpendently, but the ensemble creates coordinated regu-
probably Tec-family kinases as well—would have Src-latory properties as seen in the structures of the SH3-
like switches and clamps. Indeed, mutagenesis experi-SH2-PTK fragments from Src and Hck (Figure 1; Sicheri
ments on Abl have confirmed various predictions ofet al., 1997; Xu et al., 1997; Williams et al., 1997). Mem-
those similarities (for example, Barila´ and Superti-Furga,bers of at least two other protein kinase families—the
1998). But what about a latch? c-Abl lacks a simple,Abl/Arg and Tec kinase types—have a precisely similar
tyrosine-containing tail. Rather, it has a long set of othergrouping of domains, and it has therefore been sus-
functional elements carboxy-terminal to the kinase. Itspected that a Src-like switching mechanism might con-
inactive form also lacks any phosphorylated tyrosines.trol them. Work reported in the present issue of Cell
Experiments published last year from Superti-Furga’s(Nagar et al., 2003; Hantschel et al., 2003) now confirms
laboratory (Pluk et al., 2002) suggested that the regionthe correctness of that suspicion for c-Abl, by demon-
amino-terminal to the SH3 domain might help stabilizestrating that, like Src, it can adopt an “assembled” struc-
the autoinhibited state of the enzyme. This amino-termi-
ture in which the SH3 and SH2 domains pack against
nal “cap” bears an N-myristoyl group in one splice form
the kinase domain and clamp it into an inactive state.
of c-Abl (Abl 1b), but not in another (Abl 1a). A collabora-
Regulation by domain assembly also helps explain the tion between the groups of Kuriyan and Superti-Furga
surprising specificity of Abl inhibitors like STI571/ima- has now come up with the unexpected answer that in
tinib and the distribution of imatinib resistance muta- Abl 1b it is the N-myristoyl group at the extreme end of
tions (Azam et al., 2003 [also this issue of Cell]). the amino-terminal segment that keeps the SH3-SH2
Protein serine/threonine and tyrosine kinases all con- clamp in place (Nagar et al., 2003; Hantschel, et al.,
tain a two-lobe enzymatic domain of conserved struc- 2003). The structural details of the latching mechanism
ture (Huse and Kuriyan, 2002). The catalytic site lies in involve the same corner of the large lobe of the kinase
a cleft between the smaller, amino-terminal lobe and from which the carboxy-terminal tail emerges in Src, and
the larger, carboxy-terminal one. The two domains can the entire picture constitutes an elegant evolutionary
adopt a range of relative orientations, opening and clos- variation on the familiar, Src-like theme.
ing the active-site cleft. Within each lobe is a polypeptide How does the N-myristoyl group contribute to the
segment that has an “active” and an “inactive” confor- assembled structure? The large lobe of the kinase pre-
mation. In the small lobe, this segment is an  helix (the sents a deep, hydophobic pocket for the fatty-acid
“C-helix”) that in some kinases rotates and translates chain, but the local structure depends on whether or
with respect to the rest of the lobe, making or breaking not the myristoyl group is in place. In its absence, as
part of the catalytic site. In the large lobe, a loop (the seen in an earlier structure of the kinase domain alone
“activation loop”) reconfigures to make or break a differ- (Schindler et al., 2000), rearrangement of two  helices
ent part of the catalytic region. In most kinases, including that border the pocket destroys the docking surface for
the SH2 domain. Thus, removal of the myristoyl group
unlocks the clamp by destabilizing the SH2-kinase inter-*Correspondence: harrison@crystal.harvard.edu
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Figure 1. The Order of Domains in the Polypeptide Chains of Src and Abl, and Diagrams of Their Assembled, Autoinhibited States
In both cases, the SH3-SH2 clamp fixes the bilobed kinase domain in an inactive conformation. The domain color codes are SH3, yellow;
SH2, green; kinase small lobe, dark blue; kinase large lobe, light blue. The activation loop in the large lobe is red. Connector, linker, and
N- and C-terminal extensions are black. In Bcr/Abl, gene fusion has replaced the Abl cap by a long segment of Bcr.
action. The corresponding interactions in Abl 1a are not al., 2003). By reinforcing this sequestration, the clamp
blocks an event that would probably force disassemblyyet determined. The authors argue that hydrophobic
amino-acid residues in the 1a cap might substitute for of the autoinhibted state and effectively deregulate the
enzyme (barring subsequent removal of the phosphatethe fatty-acid side in the 1b cap, and the shape of the
pocket appears to allow such a substitution. Other inter- by a phosphatase). Src kinases in their autoinhibited
conformations also bury their activation-loop tyrosinesactions, involving the SH3-proximal end of the cap, may
also contribute: in one of the structure determinations (Schindler et al., 1999; Xu et al., 1999).
The inactive conformations of Src and Abl, reinforceddescribed by Nagar et al. (2003), there is distinct but
poorly ordered electron density attributable to this part by essentially similar clamps, differ in subtle but impor-
tant ways. In the “off” state of Src, the C-helix in theof the polypeptide chain.
In what sense is the SH3-SH2 substructure a clamp? small lobe moves out of the active site, withdrawing a
key glutamate residue. The comparable rearrangementIn solution, the two parts of the SH3-SH2 Src fragment
are quite independent, and the short connector between does not occur in Abl. Moreover, the activation loops
of the two kinases adopt dissimilar conformations inthem flexes freely (Fushman et al., 1999). But when orga-
nized into the asembled state of intact Src, the SH3- their respective autoinhibited states, and the differences
induce different conformations even in conserved partsSH2 modules have strongly correlated dynamics, as
demonstrated by some elegant and insightful simula- of the catalytic site. These observations help explain
the remarkable specificity of inhibitors such as imatinib.tions carried out by Young et al. (2001) and now repli-
cated for Abl (Nagar et al., 2003). The computations Imatinib is a 2-phenylaminopyrimidine derivative that
occupies the ATP site of the kinase. It inhibits Abl, butshow that the two submodules have correlated motions
in the assembled structure. They predict that mutation not the very closely related Src. Structures of imatinib
complexes of the Abl catalytic domain have shown thatof the SH3-SH2 connector might reduce the strength of
the clamp; indeed such mutations do diminish autoin- the drug requires an inactive kinase conformation for
binding (Schindler et al., 2000; Nagar et al., 2002). Thus,hibition, both in Src and in Abl (Young et al., 2001;
Hantschel et al., 2003). Kuriyan and co-workers have the different responses of the Abl and Src catalytic do-
mains to their autoinhibitory clamps underlie their diver-called the clamp an “inducible snap lock”, to capture
the notion that the two flexibly joined parts snap together gent sensitivities to imatinib. Strong conservation of ca-
talytic-cleft residues does not prevent longer-rangeand rigidify the bilobed kinase domain.
Why does rigidification inhibit the kinase? The cata- structural features (e.g., in the activation loops) from
imparting striking differential specifity. The inactive con-lytic cleft must open and close, at least to some extent,
to admit ATP and to release ADP. This capacity to flex, formation of Abl is very similar to that of the insulin
receptor (IR) tyrosine kinase. Imatinib does not inhibitessential to the catalytic cycle, is effectively blocked by
the snap-lock clamp assembly, which spans the two IR, however, probably because of one or a few residues
that differ from their Abl counterparts and block druglobes and directly contacts the hinge between them.
Perhaps equally important is that clamping enhances binding (Schindler et al., 2000). It does inhibit the plate-
let-derived-growth-factor-receptor (PDGFR) and theprotection of Tyr 412. This is the position at which phos-
phorylation triggers rearrangement of the activation c-kit tyrosine kinases: presumably their inactive confor-
mations resemble those of Abl and IR, without interferingloop. Tyr 412 is sequestered in the inactive conformation
of the kinase domain (Schindler et al., 2000; Nagar et amino-acid substitutions.
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Figure 2. Modes of Activation for Src and Abl: Unlatching, Unclamping, and Switching
In Src-family members, the assembled state is unlatched by dissociation of the C-terminal tail from the SH2 domain and dephosphorylation
of the exposed Tyr 527. In Abl, the assembled state is unlatched by release of the cap, anchored by a myristoyl group in Abl 1b and presumably
by alternative hydrophobic interactions in Abl 1a. Competing SH2 and SH3 ligands can unclamp the assembled regulatory appartus of Src
or Abl, and the kinase domain can then be switched into its active conformation by phosphorylation of a tyrosine in the activation loop. Linker
phosphorylation further sets the switch in Abl.
The oncoprotein product of the Phildelphia chromo- ably destabilize the assembled state of the enzyme.
They suggest that the clamp can affect imatinib sensitiv-some in patients with chronic myeoloid leukemia (CML)
is a deregulated version of Abl, in which fusion with ity by influencing the assembled-disassembled confor-
mational equilibrium and by indirectly hindering phos-the breakpoint-cluster-region product (Bcr) has deleted
much of the N-terminal cap and hence the latch mecha- phorylation of Tyr 412. Phosphorylation of the activation
loop will render the enzyme insensitive to the drug. Note,nism. Bcr fusion also leads to oligomerization, which
probably enhances transphosphorylation of Tyr 412 and however, that only if the kinase opens up occasionally
will the drug bind at all. Thus, mutations that destabilizethus accelerates the switch. Patients treated with ima-
tinib in the indolent chronic phase of CML experience the assembled state may, paradoxically, enhance inhibi-
tion by imatinib in vitro, if the measurements are donecomplete remission; those treated in the more aggres-
sive stages of the disease generally evolve drug-resis- under conditions that do not allow phosphorylation of
Tyr 412 (Roumiantsev et al., 2002; Azam et al., 2003;tance. While most patient-derived resistance mutations
are within the Bcr/Abl kinase domain, a cell-based Hantschel et al., 2003).
Kinases have become fashionable targets for thescreen for resistance mutations carried out by Daley
and coworkers identifies point changes at a number of pharmaceutical industry, not the least because of the
clinical success of imatinib in treating CML. The proper-other sites (Azam et al., 2003). The results correlate
extemely well with expectations from the structural anal- ties of the assembled state of Abl show why drug devel-
opers should look well beyond the catalytic sites of theiryses just described. Mutations conferring imatinib resis-
tance appear not just at residues that contact imatinib enzymes. Imatinib’s spectrum of targets (Abl, PDGFR,
c-kit, but not Src) corresponds not just to conservationdirectly or in parts of the kinase domain that might evi-
dently influence its conformational preferences, but also of active-site residues but also to conformational prop-
erties that extend across much of the kinase domain.in the cap, at the interfaces between the regulatory ap-
paratus and the kinase domain, in the SH3-SH2 connec- The possibility of enhancing specificity or potency for
Abl by simultaneously targeting the myristoyl pocket istor, and in the SH2-kinase linker. These mutations prob-
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Fushman, D., Xu, R., and Cowburn, D. (1999). Biochemistry 38,an obvious conclusion from the present discoveries.
10225–10230.Moreover, proper analysis of imatinib resistance clearly
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K.,requires understanding the assembled state of a multi-
Kuriyan, J., and Superti-Furga, G. (2003). Cell 112, this issue, 123–domain protein. The complexities of potential patient
456.
resistance profiles implicit in the results of Azam et al.
Huang, H., Chopra, R., Verdine, G., and Harrison, S.C. (1998). Sci-
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1998; Boyer et al., 2001). Nagar, B., Hantschel, O., Young, M.A., Scheffzek, K., Veach, D.,
What sort of control device is the latch-clamp-switch Bornmann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J.
(2003). Cell 112, this issue, 123–456.of Abl and Src? Activating inputs are likely to come in
several forms (Figure 2). Unlatching by withdrawl of the Park, S.-H., Zarrinpar, A., and Lim, W.A. (2003). Science 299, 1061–
1064.myristoyl group from its pocket is probably one form of
Pluk, H., Dorey, K., and Superti-Furga, G. (2002). Cell 108, 247–259.activation, and a specific myristoyl binding protein could
Roumiantsev, S., Shah, N.P., Gorre, M.E., Nicoll, J., Brasher, B.B.,be part of the larger control circuitry. Unclamping by
Sawyers, C.L., and Van Etten, R.A. (2002). Proc. Natl. Acad. Sci.SH3 and SH2 ligands is a second kind of potential input.
USA 99, 10700–10705.Although the phosphotyrosine pocket of Abl’s SH2 do-
Schindler, T., Sicheri, F., Pico, A., Gazit, A., Levitzki, A., and Kuriyan,main is not occupied in the assembled structure, as it is
J. (1999). Mol. Cell 3, 639–648.in Src-family kinases, the ligand-binding site is partially
Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson,occluded, and strong phophotyrosine-bearing peptides
B., and Kuriyan, J. (2000). Science 289, 1938–1942.
(e.g., docking sites on receptor tyrosine kinases) are
Sicheri, F., Moarefi, I., and Kuriyan, J. (1997). Nature 385, 602–609.
likely to trigger disassembly (Hantschel et al., 2003). SH3
Williams, J.C., Weijland, A., Gonfloni, S., Thompson, A., Courtneidge,ligands will probably do the same. Switching the enzyme
S.A., Superti-Furga, G., and Wierenga, R.K. (1997). J. Mol. Biol. 274,
into its active state, by phosphorylation of Tyr 412, is a 757–775.
third type of input. This switch will be reversible only Xu, W., Harrison, S.C., and Eck, M. (1997). Nature 385, 595–601.
through the action of a phosphatase, but it will be require Xu, W., Doshi, A., Lei, M., Eck, M.J., and Harrison, S.C. (1999). Mol.
at least partial unclamping (“breathing open” of the ki- Cell 3, 629–638.
nase) to be set in the first place. A similarly hard-to- Young, M.A., Gonfloni, S., Superti-Furga, G., Roux, B., and Kuriyan,
reverse, switch-like input is phosphorylation of Tyr 245, J. (2001). Cell 105, 115–126.
in the linker between SH2 and kinase domains (Brasher
and Van Etten, 2000). Modification of this residue breaks
the SH3-linker ineraction and prevents assembly into
the autoinhibited structure.
The assembled state of c-Abl illustrates an important
principle that modelers and redesigners of signal trans-
duction networks will need to bear in mind. There is a
limit to interchangeability. Recent work on the redesign
of MAP kinase signaling complexes has shown that
many aspects of the phosphorylation pipeline can be
preserved by installing generic tethers on the kinases
and creating a generic scaffold (Park et al., 2003). Had
the SH3 and SH2 domains been part of Src or Abl only
to recruit the kinase function to an appropriate target
or scaffold, then considerably more leeway might have
been possible in the way they could be linked to the
catalytic domain and to each other. In practice, they
form, along with the catalytic domain, an integrated
structure with critical internal coherence. Unlike many
man-made computers, which have been designed for
programmability, the hardware of biological control cir-
cuits has coevolved with its program.
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